Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Leukemia 45Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12Burkitt Lymphoma 12Leukemia, Biphenotypic, Acute 9Recurrence 8Lymphoma 8Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia, T-Cell 4Leukemia, Myeloid, Acute 3Neoplasms 2Neoplasm, Residual 2Lymphoma, T-Cell 2Down Syndrome 2Mucositis 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphoid 1Leukemia, B-Cell 1Immunoproliferative Disorders 1Hematologic Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Blast Crisis 1

Interventions

fludarabine 6Tacrolimus 6Busulfan 6blinatumomab 5Rituximab 5Cyclophosphamide 5fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Epoetin Alfa 4venetoclax 3Whole-Body Irradiation 3Methotrexate 3Darbepoetin alfa 3Alemtuzumab 3ponatinib 2ibrutinib 2entrectinib 2alectinib 2Thiotepa 2Therapeutics 2Patient Reported Outcome Measures 2Mesna 2Melphalan 2Everolimus 2Early Intervention, Educational 2Bone Marrow Transplantation 2Antilymphocyte Serum 2vandetanib 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoproliferative Disorders × pegaspargase × Other hematologic neoplasm × Clear all
NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Completed
111 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡